Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 251 to 300 of 7998 results

  1. Cost saving guidance

    NICE guidance that could generate cost savings.

  2. Technology appraisals - position statements

    On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar

  3. Chemotherapy dose standardisation: NICE position statement

    NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...

  4. Biosimilar technologies: NICE position statement

    There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...

  5. Biosimilar technologies: NICE position statement - information for the public

    Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...

  6. Participation in clinical trials and subsequent access to drugs appraised by NICE: a statement on the applicability of technology appraisal guidance

    Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...

  7. System implementation team

    We work with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area,...

  8. Into practice

    Tools and resources to help you implement guidance and quality standards at work.

  9. Digitally enabled therapies for adults with depression: early value assessment (HTE8)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....

  10. Transparency of spend

    NICE transparency of spend

  11. What we do

    Role and responsibilities of the National Institute of Health and Care Excellence

  12. Join the public involvement programme expert panel

    Join Nice's Public Involvement Programme expert panel

  13. Office for Digital Health

    The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.

  14. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel

  15. Accreditation

    NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.

  16. Library and knowledge services staff

    The resources in this section have been developed to help you deliver services to your users. Buy books, journals and databases Use the NICE...

  17. NICE committee vacancies for health, social care and other professionals and practitioners

    We're looking for health, social care and other professionals and practitioners to take an active role in producing a NICE guideline or quality standard.

  18. Buy books, journals and databases

    The NICE Electronic and Print Content Framework Agreement - enables the NHS and other health and social care related organisations to buy medical and healthcare related content.

  19. Apply to be a chair on a NICE committee

    We're looking for healthcare professionals and lay people to chair our guideline committees.

  20. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  21. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

  22. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

  23. Quick guides to social care topics

    A quick, easy way to access key information from NICE on social care topics.

  24. Prioritising our guidance topics

    We're developing a new centralised approach to prioritising our guidance topics. This will ensure that we produce guidance that is relevant, timely,...

  25. Committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  26. Our role in the Innovative Licensing and Access Pathway (ILAP)

    The Innovative Licensing and Access Pathway (ILAP) aims to streamline patient access to safe, financially sustainable and innovative medicines.

  27. NICE Advice service

    NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.

  28. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)

    Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.

  29. Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

    Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.

  30. Medical Technologies Evaluation Programme

    How to submit a new medical technology to NICE for guidance

  31. Medical technologies guidance

    Our medical technologies guidance evaluates new, innovative medical devices and diagnostics.

  32. Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)

    NICE is unable to make a recommendation on treosulfan (Trecondi) with fludarabine before allogeneic stem cell transplant for babies, children and young people aged 1 month to 17 years with non-malignant diseases. This is because Medac Pharma did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA945

  33. NICE International

    An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing

  34. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  35. CKS end user licence agreement

    CKS end user licence agreement

  36. Better research, faster: NIHR launch new funding call

    In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.

  37. How NICE manages the potential conflicts of interests of patient experts

    People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.

  38. NICE to stop supplying print copies of BNF and BNFC

    To support use of up-to-date content, and drive sustainability and digital transformation, the upcoming editions of BNF and BNFC (scheduled for distribution in October and November 2023) will be the last print editions to be supplied to the NHS in England by NICE.

  39. NHS at 75

    Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.

  40. Time to talk: about NICE's latest depression guidelines

    To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.

  41. Working at the forefront of neurodegenerative disease research

    Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.

  42. International collaboration

    Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.

  43. Increasing the capacity of our technology appraisals - the proportionate way

    Jenniffer Prescott describes how we are trialling a proportionate approach to technology appraisals, which we expect will increase our capacity by 20% from 2023/24.

  44. Using our guidance and resources in continuing professional development (CPD)

    Registered social workers must demonstrate the use of evidence and research to inform their practice in order to meet professional standards. This is echoed in Social Work England’s continuing professional development (CPD) standards.

  45. How is NICE supporting digital health technology developers?

    Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.

  46. Help shape our evidence standards framework

    Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation.

  47. Diagnostics advisory committee members

    Find out more about the diagnostics advisory committee members by reading their biographies. Dr Brian Shine (chair) Biography Brian is a

  48. How NICE is helping to build the role of the NHS on the global stage

    Kevin Miles discusses how NICE International is working to shape and improve health and care systems at home and abroad as part of the NHS Consortium for Global Health.

  49. Help shape our new service: Understanding regulations of AI and digital technology in health and social care

    As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.